businesspress24.com - / CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference
 

/ CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference

ID: 1289390

(firmenpresse) - AMES, IA -- (Marketwired) -- 12/05/13 -- In the news release, "NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference," issued earlier today by NewLink Genetics Corporation (NASDAQ: NLNK), we are advised by the company that the conference date in the first paragraph should read "Tuesday, December 10, 2013" rather than "Tuesday, December 11, 2013" as originally issued. The headline has also been updated. Complete corrected text follows.



AMES, IA -- Dec 5, 2013 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference in New York, on Tuesday, December 10, 2013 at 1:35 p.m. ET.



NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit . Patient information is available at .



Gordon Link
Chief Financial Officer
515-598-2925




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference
PBMI Research Shows Drug Benefit Design Approaches Consistent With 2012
Bereitgestellt von Benutzer: Marketwired
Datum: 05.12.2013 - 11:06 Uhr
Sprache: Deutsch
News-ID 1289390
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

AMES, IA


Phone:

Kategorie:

Hospitals, Facilities and Providers


Anmerkungen:


Diese Pressemitteilung wurde bisher 192 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"/ CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von

NewLink Genetics Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von NewLink Genetics Corporation



 

Who is online

All members: 10 564
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 73


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.